##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 6 (2024)

Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis

Cite this as:
Swiss Med Wkly. 2024;154:3698
Published
24.06.2024

Summary

BACKGROUND AND AIM: Direct-acting antivirals (DAAs) have revolutionised the management of chronic hepatitis C. We analysed the use of different generations of DAAs over time in Switzerland and investigated factors predictive of treatment failure.

METHODS: This retrospective study was conducted within the framework of the Swiss Association for the Study of the Liver and the Swiss Hepatitis C Cohort Study; it included all patients with chronic hepatitis C treated with DAAs between January 2015 and December 2019 at eight Swiss referral centres.

RESULTS: A total of 3088 patients were included; 57.3% were male, and the median age was 54 years. Liver cirrhosis was present in 23.9% of the cohort, 87.8% of whom were compensated. The overall sustained virological response (SVR) rate (defined as undetectable HCV RNA at week 12 after the first course of DAA-based treatment) was 96.2%, with an increase over time. The rate of treatment failure dropped from 8.3% in 2015 to 2.5% in 2019. Multivariable analysis revealed that female sex, the use of the latest generation of pangenotypic DAA regimens, Caucasian origin, and genotype (gt) 1 were associated with SVR, whereas the presence of active hepatocellular carcinoma (HCC), gt 3, and increasing liver stiffness were associated with treatment failure. Notably, the presence of active HCC during treatment increased the risk of DAA failure by a factor of almost thirteen.

CONCLUSIONS: SVR rates increased over time, and the highest success rates were identified after the introduction of the latest generation of pangenotypic DAA regimens. Active HCC, gt 3 and increasing liver stiffness were associated with DAA failure.

 

References

  1. Bruden DJ, McMahon BJ, Townshend-Bulson L, Gounder P, Gove J, Plotnik J, et al. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. Hepatology. 2017 Jul;66(1):37–45. 10.1002/hep.29115
  2. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):122–32. 10.1038/nrgastro.2016.176
  3. Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332–42. 10.1016/S2468-1253(22)00386-7
  4. Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al.; Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022 May;7(5):396–415. 10.1016/S2468-1253(21)00472-6
  5. Bihl F, Bruggmann P, Castro Batänjer E, Dufour JF, Lavanchy D, Müllhaupt B, et al. HCV disease burden and population segments in Switzerland. Liver Int. 2022 Feb;42(2):330–9. 10.1111/liv.15111
  6. Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, et al. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C. JAMA Intern Med. 2023 Feb;183(2):97–105. 10.1001/jamainternmed.2022.5699
  7. Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020 Feb;71(2):686–721. 10.1002/hep.31060
  8. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al.; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020 Nov;73(5):1170–218. 10.1016/j.jhep.2020.08.018
  9. Thomas DL. Global Elimination of Chronic Hepatitis. N Engl J Med. 2019 May;380(21):2041–50. 10.1056/NEJMra1810477
  10. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al.; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec;373(27):2599–607. 10.1056/NEJMoa1512610
  11. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, et al.; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec;373(27):2608–17. 10.1056/NEJMoa1512612
  12. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017 Oct;17(10):1062–8. 10.1016/S1473-3099(17)30496-6
  13. Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 Jan;378(4):354–69. 10.1056/NEJMoa1702417
  14. Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther. 2019 Apr;49(8):1052–9. 10.1111/apt.15222
  15. Müllhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly. 2021 Jan;151(304):w20399. 10.4414/smw.2021.20399
  16. Bachofner J, Valli PV, Bergamin I, Kröger A, Künzler P, Baserga A, et al.; The Swiss Hepatitis C Cohort Study. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. Swiss Med Wkly. 2018 Jan;148:w14560.
  17. Béguelin C, Suter A, Bernasconi E, Fehr J, Kovari H, Bucher HC, et al.; Swiss HIV Cohort Study. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. Liver Int. 2018 Mar;38(3):424–31. 10.1111/liv.13528
  18. Scotto R, Buonomo AR, De Pascalis S, Nerilli M, Pinchera B, Staiano L, et al. Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results. Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):1057–63. 10.1080/17474124.2021.1890029
  19. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F; Swiss Hepatitis C Cohort Study Group. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol. 2007 Aug;36(4):731–7. 10.1093/ije/dym096
  20. Arias A, Aguilera A, Soriano V, Benítez-Gutiérrez L, Lledó G, Navarro D, et al. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther. 2017;22(4):307–12. 10.3851/IMP3061
  21. Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021 Jun;41(6):1265–77. 10.1111/liv.14849
  22. Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, et al. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: results of the HCV-TARGET Study. Clin Infect Dis. 2016 Sep;63(6):776–83. 10.1093/cid/ciw387
  23. Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol. 2018 Apr;68(4):663–71. 10.1016/j.jhep.2017.11.009
  24. Daniel KE, Saeian K, Rizvi S. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. J Viral Hepat. 2020 Feb;27(2):195–204. 10.1111/jvh.13218
  25. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al.; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec;373(27):2618–28. 10.1056/NEJMoa1512614
  26. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al.; SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep;149(3):649–59. 10.1053/j.gastro.2015.05.010
  27. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017 Jun;66(6):1173–81. 10.1016/j.jhep.2017.01.020
  28. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017 Jul;67(1):32–9. 10.1016/j.jhep.2017.02.027
  29. Radhakrishnan K, Di Bisceglie AM, Reddy KR, Lim JK, Levitsky J, Hassan MA, et al. Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: an HCV-TARGET Analysis. Hepatol Commun. 2019 Aug;3(10):1388–99. 10.1002/hep4.1412
  30. Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019 Sep;71(3):473–85. 10.1016/j.jhep.2019.04.017
  31. Childs K, Davis C, Cannon M, Montague S, Filipe A, Tong L, et al. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C. J Hepatol. 2019 Dec;71(6):1099–105. 10.1016/j.jhep.2019.07.025
  32. Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, et al. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology. 2019 Feb;69(2):513–23. 10.1002/hep.30225
  33. Nguyen D, Smith D, Vaughan-Jackson A, Magri A, Barnes E, Simmonds P; STOP-HCV Consortium. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. J Hepatol. 2020 Oct;73(4):794–9. 10.1016/j.jhep.2020.05.029
  34. Cottagnoud S, Mathieu A, Perreau M, Moradpour D, Fraga M. Out of Africa: Hepatitis C virus subtype 4r as troublemaker. Schweiz Med Forum 2019;149 [Suppl 240]:22S)
  35. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013 Jul;13(7):535–42. 10.1038/nri3463
  36. Graf C, D’Ambrosio R, Degasperi E, Paolucci S, Llaneras J, Vermehren J, et al. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. JHEP Rep Innov Hepatol. 2024 Feb;6(3):100994. 10.1016/j.jhepr.2023.100994
  37. Howe AY, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, et al.; SHARED Collaborators. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep Innov Hepatol. 2022 Feb;4(5):100462. 10.1016/j.jhepr.2022.100462
  38. Popping S, Cento V, Seguin-Devaux C, Boucher CA, de Salazar A, Heger E, et al. The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. Viruses. 2021 Dec;14(1):16. 10.3390/v14010016
  39. Baumann L, Braun DL, Cavassini M, Stoeckle M, Bernasconi E, Schmid P, et al. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study. Liver Int. 2024 Jan;44(1):169–79. 10.1111/liv.15754